Contraception use and changes in young women with newly diagnosed Breast Cancer – Dana-Farber’s Breast Oncology Center
Dana-Farber’s Breast Oncology Center shared on X:
“This new study, led by Dr. Megan Tesch, assessed contraception use and changes in young women with newly diagnosed Breast Cancer. The authors highlight the complexities of contraception use as well as the need for early and improved contraceptive counseling.”
Contraception use and changes in young women with newly diagnosed breast cancer
Authors: Megan Tesch, Kimia Sorouri, Yue Zheng, Shoshana M Rosenberg, Kathryn J Ruddy, Karen M Emmons, M Caryn Dutton, Ann H Partridge
More posts featuring Dana-Farber’s Breast Oncology Center on oncodaily.com
Megan Tesch, MD, is a medical oncologist at Dana-Farber Cancer Institute, specializing in breast cancer. She also serves as an Instructor in Medicine at Harvard Medical School in Boston, Massachusetts. Her research is focused on understanding the clinical and biological factors that drive differences in outcomes for young adults with breast cancer, aiming to address and reduce disparities in this patient population.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023